Current and historical daily PE Ratio for Boiron SA (
) from 1990 to Jun 09 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Boiron stock (XPAR:BOI) PE ratio as of Jun 09 2024 is 17.14.
More Details
Boiron SA (XPAR:BOI) PE Ratio (TTM) Chart
Boiron SA (XPAR:BOI) PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1272
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| Boiron PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-10 | 17.1 | 2024-04-05 | 16.7 |
| 2024-06-07 | 17.1 | 2024-04-04 | 17.1 |
| 2024-06-06 | 17.1 | 2024-04-03 | 16.6 |
| 2024-06-05 | 17.1 | 2024-04-02 | 16.6 |
| 2024-06-04 | 16.9 | 2024-03-28 | 16.3 |
| 2024-06-03 | 17.3 | 2024-03-27 | 16.2 |
| 2024-05-31 | 17.4 | 2024-03-26 | 16.0 |
| 2024-05-30 | 17.1 | 2024-03-25 | 16.5 |
| 2024-05-29 | 17.0 | 2024-03-22 | 16.1 |
| 2024-05-28 | 16.8 | 2024-03-21 | 16.1 |
| 2024-05-27 | 16.8 | 2024-03-20 | 16.1 |
| 2024-05-24 | 16.5 | 2024-03-19 | 16.4 |
| 2024-05-23 | 16.4 | 2024-03-18 | 16.5 |
| 2024-05-22 | 16.5 | 2024-03-15 | 15.8 |
| 2024-05-21 | 16.8 | 2024-03-14 | 16.5 |
| 2024-05-20 | 16.4 | 2024-03-13 | 16.4 |
| 2024-05-17 | 16.6 | 2024-03-12 | 17.0 |
| 2024-05-16 | 17.2 | 2024-03-11 | 16.7 |
| 2024-05-15 | 16.8 | 2024-03-08 | 17.2 |
| 2024-05-14 | 16.6 | 2024-03-07 | 17.0 |
| 2024-05-13 | 16.8 | 2024-03-06 | 17.2 |
| 2024-05-10 | 16.6 | 2024-03-05 | 17.3 |
| 2024-05-09 | 16.5 | 2024-03-04 | 17.4 |
| 2024-05-08 | 16.4 | 2024-03-01 | 17.3 |
| 2024-05-07 | 16.6 | 2024-02-29 | 17.3 |
| 2024-05-06 | 16.8 | 2024-02-28 | 17.5 |
| 2024-05-03 | 16.4 | 2024-02-27 | 17.5 |
| 2024-05-02 | 16.5 | 2024-02-26 | 17.6 |
| 2024-04-30 | 16.6 | 2024-02-23 | 17.6 |
| 2024-04-29 | 16.6 | 2024-02-22 | 17.5 |
| 2024-04-26 | 16.4 | 2024-02-21 | 17.3 |
| 2024-04-25 | 16.6 | 2024-02-20 | 17.3 |
| 2024-04-24 | 16.5 | 2024-02-19 | 17.5 |
| 2024-04-23 | 16.5 | 2024-02-16 | 17.5 |
| 2024-04-22 | 16.4 | 2024-02-15 | 17.7 |
| 2024-04-19 | 16.4 | 2024-02-14 | 17.5 |
| 2024-04-18 | 16.4 | 2024-02-13 | 17.3 |
| 2024-04-17 | 16.3 | 2024-02-12 | 17.6 |
| 2024-04-16 | 16.5 | 2024-02-09 | 17.3 |
| 2024-04-15 | 16.6 | 2024-02-08 | 17.3 |
| 2024-04-12 | 16.6 | 2024-02-07 | 17.2 |
| 2024-04-11 | 16.7 | 2024-02-06 | 17.2 |
| 2024-04-10 | 16.5 | 2024-02-05 | 18.0 |
| 2024-04-09 | 16.5 | 2024-02-02 | 18.3 |
| 2024-04-08 | 16.5 | 2024-02-01 | 19.2 |
Boiron SA (XPAR:BOI) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Boiron SA
ISIN : FR0000061129
Share Class Description:
XPAR:BOI: Ordinary SharesCompare
Compare
Traded in other countries / regions
BOI.France0DTF.UKBOIRF.USABON.Germany IPO Date
1989-07-27Description
Boiron is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers